First Flight Venture Center

AthemBio is a biotechnology company focused on addressing significant challenges in bioprocessing, particularly in the manufacturing of biologics. The company develops innovative technologies and solutions aimed at combating pandemics and emerging threats from novel pathogens. AthemBio's offerings include advanced medical devices and bioprocessing systems designed to help healthcare institutions isolate and purify therapeutic antibodies. These capabilities are essential for treating COVID-19 and other pathogenic outbreaks, positioning AthemBio as a key player in the fight against infectious diseases.

Regennova is a biotechnology company dedicated to developing innovative therapeutics for inflammatory diseases and neurological disorders. The company focuses on addressing conditions such as cerebral stroke, traumatic brain injury, and Alzheimer's disease. Additionally, Regennova aims to combat sepsis and septic shock, particularly in cases involving multi-drug resistant bacteria. By pursuing novel treatment options, Regennova seeks to provide effective solutions for tau-mediated diseases, improving patient outcomes in these critical areas of healthcare.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

QUANTiSCOPE improves drug discovery by providing automated image analysis tools that are simple to integrate into research processes.

Avecris is a developer of a genetic vector platform focused on advancing genetic medicine through innovative mRNA and RNA technologies. The company offers a range of services, including cell-type specific gene expression and stable protein expression, which are designed to be non-integrating and minimize immune responses. Its platform is notable for its ability to deliver mitochondrial gene therapy and features a universal, unmodified DNA-based backbone with a modular coding region, allowing for rapid and versatile application programming. Additionally, Avecris emphasizes efficient manufacturing processes that are quick, dependable, highly scalable, and cost-effective. Through its offerings, the company enables clients to access therapeutic proteins tailored to their specific needs.

QATCH Technologies is a developer of innovative tools aimed at enhancing the biopharmaceutical industry. The company specializes in a proprietary pre-screening tool that utilizes advanced microfluidic sensor technology combined with acoustics. This technology allows for the precise processing of nanoliters of liquid, enabling researchers to assess the injectability and manufacturability of biopharmaceutical formulations at an early stage. By measuring viscosity and identifying potential manufacturing issues related to formulation, QATCH Technologies empowers biopharma researchers to select optimal injectable molecules while minimizing liquid volume requirements.

Jurata Thin Film specializes in innovative storage technology for vaccines and biologics, focusing on enhancing the manufacturing, distribution, and delivery processes. The company has developed a unique thin film matrix that stabilizes biological materials, including bacterial-based vaccines and antibody-based therapeutics. This technology allows for the long-term storage of these products at room temperature or higher, ensuring their therapeutic efficacy even in extreme conditions. The thin film can be rehydrated to recover the therapeutic payload in an aqueous solution, facilitating diverse delivery routes. By simplifying the complexities associated with vaccine and biologic storage, Jurata Thin Film aims to improve accessibility and reliability in the healthcare sector.

PrecNA is a manufacturer of customised lipid nanoparticle formulation equipment.